Core Insights - Anixa Biosciences will host its 2026 Annual Meeting of Stockholders on March 10, 2026, in a virtual format, which will be open to all interested parties, including non-stockholders [1] - The meeting will feature a corporate update from Anixa's Chairman and CEO, Dr. Amit Kumar, highlighting recent clinical milestones in the oncology pipeline [1] Clinical Progress - The final Phase 1 data from the breast cancer vaccine program met primary endpoints, demonstrating favorable tolerability and immune responses in the majority of participants [1] - Encouraging survival observations were reported in the ongoing Phase 1 ovarian cancer CAR-T trial, along with regulatory approval for substantial dose escalation [1] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel) for ovarian cancer [1] - The company collaborates with Moffitt Cancer Center to develop a novel CAR-T technology, which utilizes the natural ligand of the FSHR receptor [1] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [1]

Core Insights - Anixa Biosciences, Inc. is focused on cancer treatment and prevention, with a key highlight being Dr. Jose Conejo-Garcia's keynote speech at the SCTR 2026 Retreat, discussing the company's CAR-T technology and ongoing clinical trials [1][2]. Group 1: Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [5]. - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor instead of an antibody fragment [5]. - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in certain cancer forms [5]. Group 2: Clinical Trials and Research - The ongoing Phase 1 clinical trial of lira-cel targets adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, utilizing the FSHR-mediated CAR-T therapy [4]. - Dr. Conejo-Garcia's presentation at the SCTR 2026 Retreat will cover the advancements and findings from the ongoing clinical trial of lira-cel [2]. Group 3: Industry Collaboration - The SCTR 2026 Retreat aims to foster collaboration among pioneers in research, clinical care, and industry, showcasing innovations in advanced cell therapy, immune therapy, and oncology [3].

Core Insights - Arcellx (ACLX) is positioned as a commercially viable and scalable entity in the CAR T therapy market for multiple myeloma, distinguishing itself from other firms in the sector [1] Company Analysis - The company is perceived to be on a trajectory of high growth, operating in sectors that are expected to experience exponential expansion [1] - Arcellx is focused on innovation, which is believed to be a key driver for substantial returns in the investment landscape [1] Industry Perspective - The CAR T therapy market is characterized by intense competition, but Arcellx's unique approach may provide it with a competitive edge [1] - The emphasis on disruptive technologies within the industry aligns with broader trends in healthcare innovation, suggesting a favorable environment for companies like Arcellx [1]

Core Insights - Anixa Biosciences, Inc. is a biotechnology company focused on cancer treatment and prevention, with its Chairman and CEO, Dr. Amit Kumar, participating in the Water Tower Research Fireside Chat Series on November 11, 2025 [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2]. - The company is also developing vaccines in collaboration with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [2]. - Anixa's business model involves partnerships with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]. Clinical Programs - The breast cancer vaccine is currently in Phase 1 clinical trial status [5].